| A Phase II Study of AP (Doxorubicin, Cisplatin) Chemotherapy in Patients with Advanced Hepatocellular Carcinoma |
| Jung Ae Lee, Yoon Koo Kang, Chang Min Kim, Jin Oh Lee, Tae Woong Kang |
1Department of Internal Medicine, College of Medicine, Hallym University, Korea.
2Korea Cancer Center Hospital, Seoul, Korea.
|
|
|
|
|
|
| ABSTRACT |
PURPOSE:
Hepatocellular carcinoma (HCC) is the most common form of primary hepatic carcinoma and is considered to be a highly malignant tumor with poor prognosis. We evaluated the efficacy and toxicities of AP (doxorubicin, cisplatin) comnination chemotherapy in hepatocellular carcinoma.
MATERIALS AND METHODS:
Between October 1989 and February 1991, 21 previously untreated patients with advanced hepatocellular carcinoma were entered and treated with AP combination chemotherapy (adriamycin 60 mg/m2, D1 and cisplatin 60 mg/m2, D1, repeated every 3 weeks).
RESULTS:
Among 14 evaluable patients, there was no complete response and 5 patients (36%; 95% C.I=10~62%) achieved partial response. The median survival time of all 21 patients was 17 weeks, and 63 weeks in responders (n=5) and 14 weeks in nonresponders (n=16), and the difference in two groups was statistically significant (p<0.05). The median time to progression of 14 evaluable patients was 13 weeks, and 49 weeks in the responders (n=5) and 6 weeks in the nonresponders (n=9), and the difference in two groups was statistically significant (p<0.05). Myelosuppression was minimal and non-hematologic toxicities were gererally mild and well tolerated.
CONCLUSION:
The results suggest that the combination chemotherpy of AP seems to be an effective regimen for hepatocellular carcinoma. Further trials are recommended for its true efficacy. |
| Key words:
Advanced hepatocellular carcinoma;Chemotherapy;Adriamycin;Cisplatin |
|
PDF Links
Full text via DOI 
Download Citation 
